Recommandations en Onco-Urologie 2010 : Tumeurs urothéliales

25 novembre 2010

Auteurs : C. Pfister, M. Roupret, H. Wallerand, J.-L. Davin, H. Quintens, L. Guy, N. Houede, S. Bernardini, S. Larré, C. Mazerolles, C. Roy, D. Amsellem, F. Saint, J. Irani, M. Soulié
Référence : Prog Urol, 2010, 20, S255, suppl. S4




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Introduction



Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009 Cancer J Clin 2009 ;  59 : 225-249 [cross-ref]
Ploeg M., Aben K.K., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world World J Urol 2009 ;  27 : 289-293 [cross-ref]
Irani J., Bernardini S., Bonnal J.L., Chauvet B., Colombel M., Davin J.L., et al. Tumeurs urotheliales. Recommandations du CCAFU Prog Urol 2007 ;  17 : 1065-1098 [cross-ref]
Irani J., Bernardini S., Davin J.L., Guy L., Mazerolles C., Pfister C., et al. Les tumeurs superficielles de vessie n’existent plus Prog Urol 2008 ;  18 : 204-205 [inter-ref]

Diagnostic et bilan d’extension des tumeurs urotheliales



Irani J., Bernardini S., Bonnal J.L., Chauvet B., Colombel M., Davin J.L., et al. Tumeurs urotheliales. Recommandations du CCAFU Prog Urol 2007 ;  17 : 1065-1098 [cross-ref]
Mowatt G., Zhu S., Kilonzo M., Boachie C., Fraser C., Griffiths T.R., et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer Health Technol Assess 2010 ;  14 : 1-331
Viswanath S., Zelhof B., Ho E., Sethia K., Mills R. Is routine urine cytology useful in the haematuria clinic ? Ann R Coll Surg Engl 2008 ;  90 : 153-155 [cross-ref]
Lotan Y., Bensalah K., Ruddell T., Shariat S.F., Sagalowsky A.I., Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder J Urol 2008 ;  179 : 2164-2169 [cross-ref]
Sylvester R.J., van der Meijden A.P., Oosterlinck W., Witjes J.A., Bouffioux C., Denis L., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trials Eur Urol 2006 ;  49 : 466-467 [cross-ref]
Witjes J.A., Redorta J.P., Jacqmin D., Sofras F., Malmstrom P.U., Riedl C., et al. Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non-Muscle-Invasive Bladder Cancer :Review of the Evidence and Recommendations Eur Urol 2010 ; doi : 10.1016/j.eururo.2010.01.025.
Sadow C.A, Silverman S.G., O’Leary M.P., Signorovitch J.E. Bladder cancer detection with CT urography in an Academic Medical Center Radiology 2008 ;  249 : 195-202 [cross-ref]
May M., Brookman-Amissah S., Roigas J., Hartmann A., Storkel S., Kristiansen G., et al. Prognostic Accuracy of Individual Uropathologists in Noninvasive Urinary Bladder Carcinoma : A Multicentre Study Comparing the 1973 and 2004 World Health Organisation Classifications Eur Urol 2009 ; doi : 10.1016/j. eururo.2010.03.039.
Faivre d’Arcier B, Celhay O., Safsaf A., Zairi A., Pfister C., Soulie M., et al. Tumeur urothéliale de vessie T1 : valeur pronostique du franchissement de la muscularis mucosae (T1a/T1b). Etude multicentrique du Comité de cancérologie de l’Association : francaise d’urologie (CCAFU) Prog Urol 2010 ;  20 : 440-449 [inter-ref]
Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009 Cancer J Clin 2009 ;  59 : 225-249 [cross-ref]
Streeper N.M., Simons C.M., Konety B.R., Muirhead D.M., Williams R.D., O’Donnell M.A., et al. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer BJU Int 2009 ;  103 : 475-479 [cross-ref]
Luo B., Li W., Deng C.H., Zheng F.F., Sun X.Z., Wang D.H., et al. Utility of fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma Cancer Genet Cytogenet 2009 ;  189 : 93-97 [cross-ref]
Dillman J.R., Caoili E.M., Cohan R.H., Ellis J.H., Francis I.R., Schipper M.J. Detection of upper tract urothelial neoplasms : sensitivity of axial, coronal reformatted, and curved-planar reformatted image-types utilizing 16-row multi-detector CT urography Abdom Imaging 2008 ;  33 : 707-716 [cross-ref]
Van Der Molen A.J., Cowan N.C., Mueller-Lisse U.G., Nolte-Ernsting C.C., Takahashi S., Cohan R.H. CT urography : definition, indications and techniques. A guideline for clinical practice Eur Radiol 2008 ;  18 : 4-17 [cross-ref]
Takahashi N., Kawashima A., Glockner J.F., Hartman R.P., Leibovich B.C., Brau A.C., et al. Small (<2-cm) upper-tract urothelial carcinoma :evaluation with gadolinium-enhanced three-dimensional spoiled gradient-recalled echo MR urography Radiology 2008 ;  247 : 451-457 [cross-ref]
Lee K.S., Zeikus E., DeWolf W.C., Rofsky N.M., Pedrosa I. MR urography versus retrograde pyelography/ureteroscopy for the exclusion of upper urinary tract malignancy Clin Radiol 2010 ;  65 : 185-192 [cross-ref]
Cornu J.N., Roupret M., Carpentier X., Geavlete B., de Medina S.G., Cussenot O., et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma World J Urol 2010 ;  28 : 151-156 [cross-ref]
Tavora F., Fajardo D.A., Lee T.K., Lotan T., Miller J.S., Miyamoto H., et al. Small endoscopic biopsies of the ureter and renal pelvis: pathologic pitfalls Am J Surg Pathol 2009 ;  33 : 1540-1546 [cross-ref]

Traitement des tumeurs Tis/Ta/T1



Sylvester R.J., Van der Meijden A.P., Oosterlinck W., Witjes J.A., Bouffioux C., Denis L., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables : a combined analysis of 2596 patients from seven EORTC trials Eur Urol 2006 ;  49 : 466-477 [cross-ref]
Divrik R.T., Sahin A.F., Yildirim U., Altok M., Zorlu F. Impact of routine second trans-urethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate and disease-specific survival : a prospective randomised clinical trial Eur Urol 2010 ;  58 : 185-190 [cross-ref]
Sylvester R.J., Oosterlinck W., van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer : a meta-analysis of published results of randomized clinical trials J Urol 2004 ;  171 : 2186-2190 [cross-ref]
Huncharek M., McGarry R., Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder : results of a metaanalysis Anticancer Res 2001 ;  21 : 765-769
Lamm D.L., Riggs D.R., Traynelis C.L., Nseyo U.O. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder J Urol 1995 ;  153 : 1444-1450 [cross-ref]
Bohle A., Bock P.R. Intravesical bacilli Calmette-Guerin versus mitomycin C in superficial bladder cancer : formal meta-analysis of comparative studies on tumor progression Urology 2004 ;  63 : 682-686 [cross-ref]
Järvinen R., Kaasinen E., Sankila A., Rintala E.FinnBladder Group Long-term Efficacy of Maintenance Bacillus Calmette-Guerin versus Maintenance Mitomycin C Instillation therapy in frequently recurrent TaT1 tumours without Carcinoma In Situ : A subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up Eur Urol 2009 ;  56 : 260-265
Sylvester R.J., Brausi M.A., Kirkels W.J., Hoelti W., Calais Da Silva F., Powell P.H., et al. Long-term efficacy results of EORTC GU Group study 30 911 comparing epirubicin, bacillus Calmette-Guerin (BCG), and BCG plus isoniazid in patients with intermediate and high risk stage Ta T1 papillary carcinoma of the bladder Eur Urol 2010 ;  57 : 766-773 [cross-ref]
Ojea A., Nogueira J.L., Solsona E., Flores N., Gómez J.M., Molina J.R., et al. CUETO Group (Club Urologico Espanol De Tratamiento Oncologico) A multicenter randomized prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer : low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13,5 mg) versus mitomycin C Eur Urol 2007 ;  52 : 1398-1406 [cross-ref]
Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Bohle A., Palou-Redorta J.European Association of Urology guidelines onTaT1 (non-muscle invasive) bladder cancer Update March 2008. Arnhem, the Netherlands : European Association of Urology, 2008 Eur Urol 2008 ;  54 : 303-314[Abstract].
 [cross-ref]
Sylvester R.J., van der Meijden A.P., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer : a meta-analysis of the published results of randomized trials J Urol 2002 ;  168 : 1964-1970 [cross-ref]
Lamm D.L., Blumenstein B.A., Crissman J.D., Montie J.E., Gottesman J.E., Lowe B.A., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder : a randomized Southwest Oncology Group Study J Urol 2000 ;  163 : 1124-1129 [cross-ref]
Lebret T. Tumeurs de vessie n’infiltrant pas le muscle de haut grade (TVNIM) : quand cystectomiser ? Prog Urol 2008 ;  18 : S111-S114 [inter-ref]
Dalbagni G., Vora K., Kaag M., Cronin A., Bochner B., Donat S.M., et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer Eur Urol 2009 ;  56 : 903-910 [cross-ref]
Solsona E., Iborra I., Dumont R., Rubio-Briones J., Casanova J., Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer J Urol 2000 ;  164 : 685-689 [cross-ref]
Nieder A.M., Brausi M., Lamm D., O’Donnell M., Tomita K., Woo H., et al. Management of stage T1 tumors of the bladder : International Consensus Panel Urology 2005 ;  66 : 108-125 [inter-ref]
Colombel M., Saint F., Chopin D., Malavaud B., Nicolas L., Rischmann P. The effect of ofloxacine on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer : results of a randomized, prospective, double-blind, placebo controlled, multicenter study J Urol 2006 ;  176 : 935-939 [cross-ref]
Herr H.W., Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors J Urol 2003 ;  169 : 1706-1708 [cross-ref]
Joudi F.N., Smith B.J., O’Donnell M.A. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer Urol Oncol 2006 ;  24 : 344-348 [cross-ref]

Traitement des tumeurs de la vessie T2, N0, M0



Irani J., Bernardini S., Davin J.L., Guy L., Mazerolles C., Pfister C., et al. le Comité de Cancérologie de l’AFU Les tumeurs superficielles de la vessie n’existent plus Prog Urol 2008 ;  18 : 204-205 [inter-ref]
Gore J.L., Litwin M.S., Lai J., Yano E.M., Madison R., Setodji J., et al. Use of radical rystectomy for patients with invasive bladder Cancer J Natl Cancer Inst 2010 ;  1021 : 802-811 [cross-ref]
Gore J.L., Lai J., Setodji C.M., Litwin M.S., Saigal C.S. Mortality increases when radical cystectomy is delayed more than 12 weeks : results from a Surveillance, Epidemiology, and End Results-Medicare analysis Cancer 2009 ;  115 : 988-996 [cross-ref]
Resorlu B., Baltaci S., Resorlu M., Ergun G., Abdulmajeedm, Haliloglu A.H., et al. Prognostic significance of hydronephrosis in bladder cancer treated by radical cystectomy Urol Int 2009 ;  83 : 285-288 [cross-ref]
Grossman H.B., Natale R.B., Tangen C.M., Speights V.O., Vogelzang N.J., Devere Whight R.W., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 2003 ;  349 : 859-866 [cross-ref]
Karl A., Caroll P.R., Gshwend J.E., Knüchel R., Montorsi F., Stief C.G., et al. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer Eur Urol 2009 ;  55 : 826-835 [cross-ref]
Clark P.E., Hall M.C. Contemporary management of the urethra in patients after radical cystectomy for bladder cancer Urol Clin North Am 2005 ;  32 : 199-206 [inter-ref]
Clark P.E., Stein J.P., Groshen S.G., Miranda G., Cai J., Lieskovsky G., et al. The management of urethral transitionnal cell carcinoma after radical cystectomy for invasive bladder cancer J Urol 2004 ;  172 : 1342-1347 [cross-ref]
Hassan J.M., Cookson M.S., Smith J.A., Chang S.S. Urethral recurrence in patient following orthototopic Urinary diversion J Urol 2004 ;  172 : 1338-1341 [cross-ref]
Ali-El-Dein B., Abdel-Latif M., Mosbah A., Eraky I., Shaaban A.A., Taha N.M., et al. Secondary malignant involvement of gynecologic organs in radical cystectomy specimens in women : is it mandatory to remove these organs routinely ? J Urol 2004 ;  172 : 885-887 [cross-ref]
Shariat S.F., Svatek R.S., Tilki D., Skinner E., Karakiewicz P.I., Capitanio U., et al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy BJU Int 2010 ;  105 : 1402-1412 [cross-ref]
Lebret T. Remplacement vésical et cancer de la vessie Prog Urol 2009 ;  19 : 872-880 [inter-ref]
Herr H., Lee C., Chang S., Lerner S.For the Bladder Cancer Cooperative Group Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer : a collaborative Group report J. Urol 2004 ;  171 : 1823-1828 [cross-ref]
Lebret T., Herve J.M., Yonneau L., Barre P., Lugagne P.M., Butreau M., et al. Etude de la survie après cystectomie pour cancer de vessie A propos de 504 cas Prog Urol 2000 ;  10 : 553-560
Stenzl A., Jarolim L., Coloby P., Golia S., Bartsch G., Babjuck M., et al. Urethra-sparing cystectomy and orthotopic urinary diversion in women with malignant pelvic tumors Cancer 2001 ;  92 : 1864-1871 [cross-ref]
Kauffman D.S., Winter K.A., Shipley W.U., Heney N.M., Wallace H.J., Toonkel L.M., et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy Urology 2009 ;  73 : 833-837
Lagrange JL, Bascoul-Mollevi C, Geoffrois L, Beckendorf V, Ferrero JM, Joly F, et al. Study Group on genitor-urinary tumors (GETUG). Quality of life assessment after concurrent chemoradiation for invasive bladder cancer : results of a multicenter prospective study (GETUG 97-015). Int Radiol Oncol Biol Phys 2010 [In press].
Fahmy N., Aprikian A., Tanguay S., Mahmud S.M., Al-Otaibi M., Jeyaganth S., et al. Practice patterns and recurrence after partial cystectomy for bladder cancer World J Urol 2010 ;  28 : 419-423 [cross-ref]
Kassouf W., Swanson D., Kamat A.M., Leibovici D., Siefker-Radtke A., Munsell M.F. Grossmabladder : a contemporary review of the M. D. Anderson Cancer Center experience J Urol 2006 ;  175 : 2058-2062 [cross-ref]
Van Der Steen-Banasik E., Ploeg M., Witjes J.A., Van Rey F.S., Idema J.G., Heijbroek R.P., et al. Brachytherapy versus cystectomy in solitary bladder cancer : a case control, multicentre, East-Netherlands study Radioth Oncol 2009 ;  93 : 357-367

Traitement des tumeurs de la vessie à haut risque de progression metastatique de stade T3 NX ou Tx-N1-2



Skinner D.G. Management of invasive bladder cancer : a meticulous pelvic node dissection can make a difference J Urol 1982 ;  128 : 34-36 [cross-ref]
Stein J.P., Cai J., Groshen S., Skinner D.G. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy : concept of lymph node density J Urol 2003 ;  170 : 35-41 [cross-ref]
Abdel-Latif M., Abol-Enein H., El Baz M., Ghoneim M.A. Nodal involvement in bladder cancer cases treated with radical cystectomy : incidence and prognosis J Urol 2004 ;  172 : 85-89 [cross-ref]
Giri P.G., Walsh J.W., Hazra T.A. Computed tomography in the management of bladder carcinoma Int J Radiat Oncol Biol Phys 1984 ;  10 : 1121-1125
Wolff S.J. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy J Urol 1995 ;  153 : 993-999
Thoeny H.C., Triantafyllou M., Birkhaeuser F.D., Froehlich J.M., Tshering D.W., Binser T., et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients Eur Urol 2009 ;  55 : 761-769 [cross-ref]
Kibel A.S., Dehdashti F., Katz M.D., Klim A.P., Grubb R.L., Humphrey P.A., et al. Prospective study of [18 F] fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma J Clin Oncol 2009 ;  27 : 4314-4320 [cross-ref]
Herr H.W., Donat S.M. Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy J Urol 2001 ;  165 : 62-64 [cross-ref]
Winquist E., Kirchner T.S., Segal R., Chin J., Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder : a systematic review and meta-analysis J Urol 2004 ;  171 : 561-569 [cross-ref]
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer : update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration Eur Urol 2005 ;  48 : 202-205
Lebret T., Herve J.M., Yonneau L., Molinie V., Barre P., Lugagne P.M., et al. After cystectomy, is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer ? Eur Urol 2002 ;  42 : 344-349 [cross-ref]
Konety B.R., Dhawan V., Allareddy V., Joslyn S.A. Impact of malpractice caps on use and outcomes of radical cystectomy for bladder cancer : data from the surveillance, epidemiology, and end results program J Urol 2005 ;  173 : 2085-2089 [cross-ref]
Poulsen A.L., Horn T., Steven K. Radical cystectomy : extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall J Urol 1998 ;  160 : 2015-2019 [cross-ref]
Bochner B.H., Cho D., Herr H.W., Donat M., Kattan M.W., Dalbagni G. Prospectively packaged lymph node dissections with radical cystectomy : evaluation of node count variability and node mapping J Urol 2004 ;  172 : 1286-1290 [cross-ref]
Liedberg F., Mansson W. Lymph node metastasis in bladder cancer Eur Urol 2006 ;  49 : 13-21 [cross-ref]
Mills R.D., Turner W.H., Fleischmann A., Markwalder R., Thalmann G.N., Studer U.E. Pelvic lymph node metastases from bladder cancer : outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy J Urol 2001 ;  166 : 19-23 [cross-ref]
Bruins H.M., Huang G.J., Cai J., Skinner D.G., Stein J.P., Penson D.F. Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy J Urol 2009 ;  182 : 2182-2187 [cross-ref]
Sternberg C.N. Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation Semin Oncol 2007 ;  34 : 122-128 [cross-ref]
Bochner B.H., Kattan M.W., Vora K.C. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer J Clin Oncol 2006 ;  24 : 3967-3972

Prise en charge du cancer de la vessie m+



Irani J., Bernardini S., Bonnal J., Chauvet B., Colombel M., Davin J.L., et al. Tumeurs urothéliales Prog Urol 2007 ;  17 : 1065-1098 [cross-ref]
Bamias A., Tiliakos I., Karali M.D., Dimopoulos M.A. Systemic chemotherapy in inoperable or metastatic bladder cancer Ann Oncol 2006 ;  17 : 553-561 [cross-ref]
Von Der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in with bladder cancer J Clin Oncol 2005 ;  23 : 4602-4608 [cross-ref]
Kibel A.S., Dehdashti F., Katz M.D., Klim A.P., Grubb R.L., Humphrey P.A., et al. Prospective study of [18 F] fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma J Clin Oncol 2009 ;  27 : 4314-4320 [cross-ref]
Jessen C., Agerbaek M., Von Der Maase H. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy Acta Oncol 2009 ;  48 : 411-417 [cross-ref]
Sternberg C.N, Yagoda A., Scher H.I., Watson R.C., Geller N., Herr H.W., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium, Efficacy and patterns of response and relapse Cancer 1989 ;  64 : 2448-2458 [cross-ref]
Saxman S.B., Propert K.J., Einhorn L.H., Crawford E.D., Tannock I., Raghavan D., et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma : a cooperative Group study J Clin Oncol 1997 ;  15 : 2564-2569 [cross-ref]
Von Der Maase H., Hansen S.W., Roberts J.T., Dogliotti L., Oliver T., Moore M.J., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer : results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 2000 ;  18 : 3068-3077 [cross-ref]
Sternberg C.N., de Mulder P.H., Schornagel J.H., Théodore C., Fossa S.D., van Oosterom A.T., et al. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors : European Organization for Research and Treatment of Cancer Protocol no. 30924 J Clin Oncol 2001 ;  19 : 2638-2646 [cross-ref]
Bellmunt J., Von Der Maase H., Mead G.M., Heyer J., Houede N., Paz-Ares G., et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy ; EORTC30987/Intergroup Study J Clin Oncol 2007 ;  25 : 5030Abstract.
Von Der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium Expert Rev Anticancer Ther 2003 ;  3 : 11-19 [cross-ref]
de Witt R. Overview of bladder cancer trials in the European Organization for Research and Treatment Cancer 2003 ;  97 : 2120-2126
Bellmunt J., Ribas A., Eres N., Albanell J., Almanza C., Bermejo B., et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma Cancer 1997 ;  80 : 1966-1972 [cross-ref]
Dogliotti L., Carteni G., Siena S., Bertetto O., Martoni A., Bono A., et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium : results of a randomized phase 2 trial Eur Urol 2007 ;  52 : 134-141 [cross-ref]
Lin C.C., Hsu C.H., Pu Y.S., Vogelzang N.J. Systemic therapy for metastatic urothelial carcinoma BJU Int 2008 ;  101 : 795-803 [cross-ref]
Bellmunt J., Theodore C., Demkov T., Komyakov B., Sengelov L., Daugaard G., et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract J Clin Oncol 2009 ;  27 : 4454-4461 [cross-ref]
Vaishampayan U. Systemic Therapy of Advanced Urothelial Cancer Curr Treat Options Oncol 2009 ;  10 : 256-266 [cross-ref]
Bradley D., Daignault S., Smith D.C., Nanus D., Tagawa S., Stadler W.M., et al. Maintenance sunitinib post-chemotherapy (CT) in patients with advanced urothelial carcinoma (UC) : A randomized placebo controlled phase II trial J Clin Oncol 2009 ;  27 : 5073Abstract.
Siefker-Radtke A.O., Walsh G.L., Pisters L.L., Shen Y., Swanson D.A., Logothetis C.J., et al. Is there a role for surgery in the management of metastatic urothelial cancer ? The M.D. Anderson experience J Urol 2004 ;  171 : 145-148 [cross-ref]

Traitement des tumeurs de la voie excrétrice supérieure



Irani J., Bernardini S., Bonnal J.L., Chauvet B., Colombel M., Davin J.L., et al. Tumeurs urotheliales. Recommandations du CCAFU Prog Urol 2007 ;  17 : 1065-1098 [cross-ref]
Margulis V., Shariat S.F., Matin S.F., Kamat A.M., Zigeuner R., Kikuchi E., et al. Outcomes of radical nephroureterectomy : a series from the Upper Tract Urothelial Carcinoma Collaboration Cancer 2009 ;  115 : 1224-1233 [cross-ref]
Raman J.D., Ng C.K., Scherr D.S., Margulis V., Lotan Y., Bensalah K., et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy Eur Urol 2010 ;  57 : 1072-1079 [cross-ref]
Remzi M., Haitel A., Margulis V., Karakiewicz P., Montorsi F., Kikuchi E., et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy : a multi-institutional analysis of 1363 patients BJU Int 2009 ;  103 : 307-311 [cross-ref]
Shariat S.F., Godoy G., Lotan Y., Droller M., Karakiewicz P.I., Raman J.D., et al. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy BJU Int 2010 ; 1672-1677
Lughezzani G., Sun M., Perrotte P., Shariat S.F., Jeldres C., Budaus L., et al. Should Bladder Cuff Excision Remain the Standard of Care at Nephroureterectomy in Patients with Urothelial Carcinoma of the Renal Pelvis ? A population-based study Eur Urol 2010 ;  57 : 956-962 [cross-ref]
Waldert M., Karakiewicz P.I., Raman J.D., Remzi M., Isbarn H., Lotan Y., et al. A delay in radical nephroureterectomy can lead to upstaging BJU Int 2010 ;  105 : 812-817 [cross-ref]
Kikuchi E., Margulis V., Karakiewicz P.I., Roscigno M., Mikami S., Lotan Y., et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma J Clin Oncol 2009 ;  27 : 612-618 [cross-ref]
Kim D.S., Lee Y.H., Cho K.S., Cho N.H., Chung B.H., Hong S.J. Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma Urology 2010 ;  75 : 328-332 [inter-ref]
Lughezzani G., Jeldres C., Isbarn H., Shariat S.F., Sun M., Pharand D., et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma Urology 2010 ;  75 : 118-124 [inter-ref]
Roscigno M., Shariat S.F., Margulis V., Karakiewicz P., Remzi M., Kikuchi E., et al. The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma : how many lymph nodes should be removed ? Eur Urol 2009 ;  56 : 512-518
Roupret M., Smyth G., Irani J., Guy L., Davin J.L., Saint F., et al. Oncological risk of laparoscopic surgery in urothelial carcinomas World J Urol 2009 ;  27 : 81-88 [cross-ref]
Capitanio U., Shariat S.F., Isbarn H., Weizer A., Remzi M., Roscigno M., et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy : a multi-institutional analysis of 1249 cases Eur Urol 2009 ;  56 : 1-9 [cross-ref]
Kamihira O., Hattori R., Yamaguchi A., Kawa G., Ogawa O., Habuchi T., et al. Laparoscopic radical nephroureterectomy : a multicenter analysis in Japan Eur Urol 2009 ;  55 : 1397-1407
Simone G., Papalia R., Guaglianone S., Ferriero M., Leonardo C., Forastiere E., et al. Laparoscopic versus open nephroureterectomy : perioperative and oncologic outcomes from a randomised prospective study Eur Urol 2009 ;  56 : 520-526 [cross-ref]
Jeldres C., Lughezzani G., Sun M., Isbarn H., Shariat S.F., Budaus L., et al. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter J Urol 2010 ;  183 : 1324-1329 [cross-ref]
Roupret M., Traxer O., Tligui M., Conort P., Chartier-Kastler E., Richard F., et al. Upper urinary tract transitional cell carcinoma : recurrence rate after percutaneous endoscopic resection Eur Urol 2007 ;  51 : 709-714 [cross-ref]
Hellenthal N.J., Shariat S.F., Margulis V., Karakiewicz P.I., Roscigno M., Bolenz C., et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma : results from the Upper Tract Urothelial Carcinoma Collaboration J Urol 2009 ;  182 : 900-906 [cross-ref]
O’Donnell P.H., Stadler W.M. The role of chemotherapy in upper tract urothelial carcinoma Adv Urol 2009 ; 419028
Song Y.S., Cho J.S., Cho K.S., Doo S.H., Chung B.H., Kim S.J., et al. Efficacy of adjuvant gemcitabine-cisplatin chemotherapy : a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract Urol Int 2010 ;  85 : 47-51 [cross-ref]






© 2010 
Elsevier Masson SAS. Tous droits réservés.